With Organic Nitrogen Containing Compound Patents (Class 514/162)
-
Publication number: 20120121723Abstract: An antimicrobial composition, including a synergistic combination of three or more agents as an active ingredient. Each of the three or more potentiating agents can be selected from the following types of compounds: sequestering agents, carbohydrates and carbohydrate derivatives, terpenes/terpenoids, amines and amine derivatives, plant-derived oils, sulfonates, phenols, fatty acids, dibenzofuran derivatives, organo isothiocyanates, quaternary ammonium compounds, peroxides and peroxide donors, and macrolide polyenes. At least two of the three or more potentiating agents are not of the same type of compound. The antimicrobial composition can have strong antimicrobial efficacy in control of microorganisms having resistance to currently used antimicrobials.Type: ApplicationFiled: January 25, 2012Publication date: May 17, 2012Applicant: Sterilex Technologies, LLCInventors: Pradip Mookerjee, Shira Kramer, Alexander Josowitz, April Zambelli-Weiner
-
Publication number: 20120121724Abstract: The present invention is related to the composition and methods of manufacture of orally-dissolvable, edible films as a vehicle for the non-invasive administration of nitroglycerin, as well as other therapeutic agents either with or without nitroglycerin, through the mucosal tissues of the oral cavity. The films include a water soluble film-forming polymer such as pullulan. Methods for producing the films are also disclosed.Type: ApplicationFiled: January 20, 2012Publication date: May 17, 2012Inventor: Todd Maibach
-
Patent number: 8178516Abstract: This invention defines novel compositions that can be used for clinical treatment of a class of chronic inflammatory diseases. Increased generation of carbonyl substances, namely aldehydes and ketones, occurs at sites of chronic inflammation and is common to the etiologies of all of the clinical disorders addressed herein. Such carbonyl substances are cytotoxic and additionally serve to perpetuate and disseminate the inflammatory process. This invention defines use of compositions, the orally administered required primary agents of which are primary amine derivatives of benzoic acid capable of covalently reacting with the carbonyl substances. p-Aminobenzoic acid (or PABA) is an example of the required primary agent of the present invention. PABA has a small molecular weight, is water-soluble, has a primary amine group which reacts with carbonyl-containing substances and is tolerated by the body in relatively high dosages for extended periods.Type: GrantFiled: February 20, 2008Date of Patent: May 15, 2012Assignee: Sylvan Labs, LLCInventor: Howard K. Shapiro
-
Publication number: 20120111756Abstract: Disclosed are enema solutions or suspensions comprising 5-aminosalicylic acid, or a pharmaceutically acceptable salt or ester thereof, and N-acetylcysteine, or a pharmaceutically acceptable salt or ester thereof, methods of preparing the same, and bottles and packages containing the same.Type: ApplicationFiled: December 16, 2009Publication date: May 10, 2012Applicant: ALTHEUS THERAPEUTICS, INC.Inventors: Adam Payne, Dennis Hair, Justin Briggs, Richard Harty, Sachin Malhorta
-
Publication number: 20120100077Abstract: Disclosed is a mixture of amphipathic molecules and a method for modifying cells in vivo by way of membrane fusion with these molecules.Type: ApplicationFiled: July 8, 2010Publication date: April 26, 2012Applicant: FORSCHUNGSZENTRUM JUELICH GMBHInventors: Bernd Hoffmann, Agnes Csiszar, Nils Hersch, Rudolf Merkel
-
Publication number: 20120093738Abstract: The present invention relates to taste-masked oral formulations of influenza antivirals. The taste-masked pharmaceutical formulations for oral administration comprise one or more influenza antivirals, at least one taste-masking agent and at least one pharmaceutically acceptable excipient. Further, the taste-masked influenza antiviral formulations of the present invention are provided in the form of dispersible tablets, effervescent tablets, orally disintegrating tablets, chewable tablets, bite-dispersion tablets or the like, wherein the bitter taste of influenza antivirals is masked thereby providing palatable formulations.Type: ApplicationFiled: June 10, 2010Publication date: April 19, 2012Applicant: Rubicon Research Private LimitedInventors: Pratibha Sudhir Pilgaonkar, Maharukh Tehmasp Rustomjee, Anilkumar Surendrakumar Gandhi
-
Publication number: 20120093938Abstract: The compositions of the present invention comprise a therapeutically effective amount of particles consisting of diphenhydramine or pharmaceutically acceptable salts thereof, optionally in combination with another drug such as pseudoephedrine, or phenylephrine and hydrocodone, in combination with rapidly-dispersing microgranules comprising a disintegrant and a sugar alcohol and/or a saccharide. These compositions are useful in treating the symptoms of one or more diseases or conditions in which diphenhydramine (alone or in combination with one or two other drugs) is a therapeutically effective, e.g. allergic rhinitis, sinusitis, upper respiratory tract infections, motion sickness, Parkinson's disease, insomnia, the common cold, and nighttime pain management, particularly for subjects or patients with dysphagia, and people ‘on the move’.Type: ApplicationFiled: July 14, 2011Publication date: April 19, 2012Applicant: EURAND INC.Inventors: Gopi M. VENKATESH, Jin-Wang LAI, Phillip PERCEL, Craig KRAMER
-
Publication number: 20120076841Abstract: Individualized porous particles having a volume-average diameter of less than or equal to 10 ?m and a specific surface area of greater than or equal to 1 m2/g, and that include at least one cosmetically or pharmaceutically active compound present at least inside the particles.Type: ApplicationFiled: December 5, 2011Publication date: March 29, 2012Applicant: L'OREALInventors: Jean-Thierry SIMONNET, Bruno Biatry, Didier Saint-Leger
-
Publication number: 20120077784Abstract: The present invention relates to compositions, kits and methods for treating skin at sites of concerns such as infectious lesions and/or points of insertion of an insertable medical device to prevent contamination such as infections or protein absorption that may interfere with the function of the device. The composition can be a topical skin treatment composition that includes polyethylene glycol (PEG), triclosan, one or more of a salicylate, bronopol, and an acrylic emulsion, and, optionally, a solvent.Type: ApplicationFiled: June 3, 2010Publication date: March 29, 2012Applicant: EX-TEX LLCInventor: Richard James Whitbourne
-
Publication number: 20120053158Abstract: The present invention refers to a pharmaceutical preparation comprising an ionic type complex of acetyl salicylic acid and L-glutamic acid for use in the prevention or reduction of side-effects on stomach tissue associated with an oral administration of acetyl salicylic acid.Type: ApplicationFiled: May 10, 2010Publication date: March 1, 2012Inventors: Ehab Ahmed Fouad Ahmed, Fars Kaed M. Alanazi, Mahmoud El-Badry Abdelmotaleb Abdelrahman, Ibrahim Abdullah Ibrahim Alsarra
-
Patent number: 8119618Abstract: Inflammatory bowel diseases are represented by two idiopathic disorders, which include ulcerative colitis and Crohn's disease. Ulcerative colitis is restricted to the colon and involves uncertain and inflammation of the lining (mucosa) of the large intestine. Crohn's disease, on the other hand, can involve the mucosa of the small and/or large intestine and may involve deeper layers of the bowel wall. The present invention is a combination of 5-aminosalicylic acid and one or more antioxidants (e.g., N-acetylcysteine) for treating such inflammatory bowel diseases.Type: GrantFiled: March 11, 2009Date of Patent: February 21, 2012Assignee: The Board of Regents of the University of OklahomaInventor: Richard F. Harty
-
Publication number: 20120010075Abstract: The present invention relates to the use of mixtures containing hydrazone compounds and copper for controlling the growth of fungi.Type: ApplicationFiled: January 14, 2010Publication date: January 12, 2012Applicant: Dow Agrosciences LLCInventors: David H. Young, Steven Howard Shaber, Cruz Avila-Adame, Nneka T. Breaux, James M. Ruiz, Thomas L. Siddall, Jeffery D. Webster
-
Publication number: 20110312890Abstract: This invention relates to pharmaceutical compounds and nutritional supplements that are acetylated derivatives of naturally occurring amino acids and acetylated derivatives of peptides derived from naturally occurring amino acids containing hydroxyl groups. They are as useful as anti-platelet drugs, and as nutritional supplements.Type: ApplicationFiled: August 1, 2011Publication date: December 22, 2011Applicant: SIGNATURE R&D HOLDINGS, LLCInventor: V. Ravi Chandran
-
Publication number: 20110288360Abstract: Described herein are compositions for neutralization and decontamination of toxic chemical and biological agents. In one embodiment, the subject matter discloses a nontoxic, non-corrosive composition capable of neutralizing and decontaminating toxic chemical and biological agents in a very short period of time. The present subject matter finds utility in a great number of occasions, including, but not limited to, military actions or terrorist attacks where chemical or biological agents are utilized.Type: ApplicationFiled: August 13, 2008Publication date: November 24, 2011Applicant: SUNREZ CORPORATIONInventors: Paul M. Puckett, Mark Livesay, Katherine S. Clement
-
Publication number: 20110262558Abstract: An improved composition for skin cleansing and protection is disclosed. The composition contains an effective amount of at least one alpha-hydroxyl acid or a pharmaceutically acceptable salt thereof, at least one base, one surfactant and one skin protectant. Various additives and excipients may be included in the formulation. The improved composition disclosed herein achieves a higher bacteria killing rate and shows longer action duration. The disclosed composition is capable of penetrating deep into the skin which allows for delivery of more anti-microbials to sites that are at a higher risk of being infected. Various modifications of the improved composition are also disclosed.Type: ApplicationFiled: April 27, 2011Publication date: October 27, 2011Inventors: Roger Huckfeldt, Phillip Finley
-
Publication number: 20110263545Abstract: The present invention provides hepatoprotectant acetaminophen mutual prodrugs, which have an acetaminophen moiety covalently linked to a second moiety that may act as a hepatoprotectant against acetaminophen hepatotoxicity. Additionally, acetaminophen mutual prodrugs may have improved water solubility which may provide better suitability for parenteral and other dosage forms relative to administration of acetaminophen. Also provided are methods of treating a disease or condition that is responsive to acetaminophen (such as fever, pain and ischemic injury) using hepatoprotectant acetaminophen mutual prodrugs, as well as kits and unit dosages.Type: ApplicationFiled: May 20, 2009Publication date: October 27, 2011Inventors: Naweed Muhammad, Keith R. Bley, Jeffrey Tobias
-
Publication number: 20110251161Abstract: A personal care composition comprising a eutectic mixture, the eutectic mixture comprising an alkyl monoethanolamide having an alky chain length from 10 to 14.Type: ApplicationFiled: July 31, 2009Publication date: October 13, 2011Inventors: Jason Shaun Burry, Richard Livesey Evans, Caroline Alexandra Hall, Ezat Khoshdel
-
Publication number: 20110245208Abstract: A method of combating a somatosensory disorder in a subject, comprising administering to the subject an effective amount of a composition comprising bupranolol and/or pharmaceutically acceptable derivative(s) thereof. Compositions useful for such administration are described, including salts, esters, solvates, etc. of tert-butyl[3-(2-chloro-5-methylphenoxy)-2-hydroxypropyl]amine, in which such salt, ester, solvate, etc. compound is in enantiomeric excess or homoenantiomeric in the R isomer thereof, or is formulated with racemic mixtures of the R and S stereoisomers of the salts, esters, solvates, etc. of tert-butyl[3-(2-chloro-5-methylphenoxy)-2-hydroxypropyl]amine. Combination therapy compositions of opioid receptor agonists and such compounds are also described. A method is disclosed of referential genotypic screening of candidate subjects in connection with therapeutic intervention using the compositions of the disclosure to combat the somatosensory disorder.Type: ApplicationFiled: March 30, 2011Publication date: October 6, 2011Applicant: ALGYNOMICS INC.Inventors: Luda Diatchenko, William Maixner
-
Publication number: 20110230816Abstract: The present disclosure provides hydrogels that are suitable for drug delivery. In embodiments, hydrogels of the present disclosure may be used for transdermal delivery of bioactive agents, including drugs. The hydrogels of the present disclosure may also be useful as conductive compositions for use with electrodes.Type: ApplicationFiled: August 31, 2010Publication date: September 22, 2011Applicant: TYCO HEALTHCARE GROUP LPInventor: Warren Copp-Howland
-
Publication number: 20110217301Abstract: The present invention relates to a method for treating and screening for compounds for the treatment of sepsis. More specifically, the treatment and screening methods are based on the discovery that granzyme B containing platelets (GzmB-platelet) causes apoptosis by direct contact with cells.Type: ApplicationFiled: April 6, 2011Publication date: September 8, 2011Applicant: THE CHILDREN'S RESEARCH INSTUTEInventor: ROBERT J. FREISHTAT
-
Publication number: 20110218104Abstract: Disclosed are pesticide compositions that utilize biodiesel as a solvent. The disclosed compositions may be utilized for controlling pests, such as nematodes and weeds, and for enhancing growth of plants.Type: ApplicationFiled: March 3, 2010Publication date: September 8, 2011Applicant: AUBURN UNIVERSITYInventors: R. Rodriguez-Kabana, Lee J. Simmons, C. Robert Taylor
-
Publication number: 20110151024Abstract: The present invention relates to compositions and methods for preventing migraines. The migraine prophylaxis composition is a single dosage form comprising at least one form of elemental magnesium and at least one NSAID. The prophylaxis composition, comprising at least one form of elemental magnesium and a therapeutically effective concentration of acetylsalicylic acid may also provide cardiac protection and prevent cardiovascular diseases.Type: ApplicationFiled: March 1, 2011Publication date: June 23, 2011Inventor: Alexander Mauskop
-
Publication number: 20110144055Abstract: The use of a pharmaceutical regimen to deter in an individual, as the individual ages, the development of a cardiovascular disease (CVD) or Alzheimer's disease or to treat an individual who has CVD or Alzheimer's, the individual ingesting on a daily basis a regimen comprising pharmaceutically effective amounts of magnesium salicylate and naproxen, the amount of the magnesium salicylate being no greater than about 260 mg, and also the use of a pharmaceutical regimen to treat an individual who has Type 2 diabetes, the regimen being ingested daily by the individual and comprising pharmaceutically effective amounts of at least one glucose-lowering drug and magnesium salicylate in an amount no greater than about 260 mg.Type: ApplicationFiled: September 4, 2009Publication date: June 16, 2011Inventors: Anthony I. Rozmanith, Jolan S. Rozmanith
-
Publication number: 20110136735Abstract: The present invention provides a compound of formula I; a method for manufacturing the compounds of the invention, and its therapeutic uses. The present invention further provides a combination of pharmacologically active agents and a pharmaceutical composition.Type: ApplicationFiled: November 30, 2010Publication date: June 9, 2011Inventors: David BARNES, Gregory Raymond BEBERNITZ, Scott Louis COHEN, Robert Edson DAMON, Robert Francis DAY, Monish JAIN, Rajeshri Ganesh KARKI, Louise Clare KIRMAN, Tajesh Jayprakash PATEL, Brian Kenneth RAYMER, Herbert Franz SCHUSTER, Wei ZHANG
-
Publication number: 20110117187Abstract: The present invention relates to pharmaceutical, cosmetic and cosmeceutical topical compositions containing polyisoprenyl-protein inhibitor compounds and methods useful in the promotion of healthy epithelium and the treatment of epithelial-related conditionsType: ApplicationFiled: December 15, 2010Publication date: May 19, 2011Applicant: SIGNUM BIOSCIENCES, INC.Inventors: Jeffry B. Stock, Joel Gordon, Maxwell Stock
-
Patent number: 7935689Abstract: Agents useful for the treatment of various metabolic disorders, such as insulin resistance syndrome, diabetes, polycystic ovary syndrome, hyperlipidemia, fatty liver disease, cachexia, obesity, atherosclerosis and arteriosclerosis are disclosed, compound of the formula (I): wherein n is 1 or 2; m is 0, 1, 2, 3, 4, 5, 6, 7 or 8; q is 0 or 1; t is 0 or 1; R1 is alkyl having from 1 to 3 carbon atoms; R2 is hydrogen, halo, alkyl having from 1 to 3 carbon atoms, or alkoxy having from 1 to 3 carbon atoms; R3 and R4 together are alkyl having two or three carbon atoms; or R3 and R4 are the same as each other and each is methyl or ethyl; R5 is hydrogen or alkyl having from one to six carbon atoms.Type: GrantFiled: May 11, 2007Date of Patent: May 3, 2011Assignee: Wellstat Therapeutics CorporationInventors: Shalini Sharma, Reid W. von Borstel
-
Patent number: 7928092Abstract: Methods and formulations for treating inflammatory bowel disease are disclosed. The methods and formulations include, but are not limited to, methods and formulations for delivering effective concentrations of 4-aminosalicylic acid and/or 5-aminosalicylic acid to affected areas of the intestine. The methods and formulations comprise modified-release elements, providing for drug delivery to the affected or desired area. Diseases and conditions treatable with the present invention include Crohn's disease and ulcerative colitis.Type: GrantFiled: June 10, 2010Date of Patent: April 19, 2011Assignee: AGI Therapeutics Ltd.Inventors: John Devane, Jackie Butler
-
Publication number: 20110071117Abstract: Disclosed herein are compositions comprising 5-aminosalicylic acid (5-ASA), or a pharmaceutically acceptable salt thereof and an antioxidant, or a pharmaceutically acceptable salt thereof. Also disclosed herein are methods of treating an inflammatory bowel disease in a subject, reducing cytokine gene expression in colonic tissue of a subject, and reducing myeloperoxide activity in colonic tissue of a subject, comprising administering to the subject a therapeutically effective amount of a composition comprising 5-ASA, or a pharmaceutically acceptable salt thereof, and an antioxidant, or a pharmaceutically acceptable salt thereof.Type: ApplicationFiled: May 14, 2009Publication date: March 24, 2011Applicant: The Board of Regents of the University of OklahomaInventor: Richard F. Harty
-
Publication number: 20110070316Abstract: The present invention relates to compositions comprising quaternary ammonium compounds and essential oils or individual constituents thereof which exhibit enhanced antimicrobial effects. Such combinations may be comprised in lotions, gels, creams, soaps, etc. for application to skin or mucous membranes. The invention is based, at least in part, on the observation that synergistic antimicrobial effects are achieved with combinations of essential oils or individual constituents thereof and low concentrations of quaternary ammonium compounds.Type: ApplicationFiled: November 29, 2010Publication date: March 24, 2011Inventors: Shanta M. Modak, Milind S. Shintre, Trupti Gaonkar, Lauserpina Caraos
-
Publication number: 20110071118Abstract: A novel pharmaceutical composition is provided by which nonsteroidal anti-inflammatory drugs (NSAIDs) are added directly to phospholipid-containing oil such as lecithin oils or to a bio-compatible oil to which an phospholipid has been added to make a NSAID-containing formulation that possess low gastrointestinal (GI) toxicity and enhanced therapeutic activity to treat or prevent inflammation, pain, fever, platelet aggregation, tissue ulcerations and/or other tissue disorders. The composition of the invention are in the form of a non-aqueous solution, paste, suspension, dispersion, colloidal suspension or in the form of an aqueous emulsion or microemulstion for internal, oral, direct or topical administration.Type: ApplicationFiled: September 16, 2010Publication date: March 24, 2011Applicant: The Board of Regents of the University of Texas SystemInventor: Lenard M. Lichtenberger
-
Patent number: 7910568Abstract: The present invention provides new derivatives of 4- or 5-aminosalicylic acid, and a pharmaceutical composition containing these derivatives of 4- or 5-aminosalicylic acid as active ingredients, useful for the treatment of intestinal diseases such as inflammatory bowel disease (IBD) and irritable bowel syndrome (IBS) and for the prevention/treatment of colon cancer. More particularly, these derivatives comprise a hydrogen sulfide releasing moiety linked via an azo, an ester, an anhydride, a thioester or an amide linkage to a molecule of 4- or 5-aminosalicylic acid. Furthermore, the present invention provides a process for preparing these compounds and their use for treating IBD and IBS and the prevention/treatment of colon cancer.Type: GrantFiled: March 31, 2006Date of Patent: March 22, 2011Assignee: Antibe Therapeutics Inc.Inventors: John L. Wallace, Giuseppe Cirino, Giuseppe Caliendo, Anna Sparatore, Vincenzo Santagada, Stefano Fiorucci
-
Publication number: 20110065677Abstract: A novel pharmaceutical composition is provided by which nonsteroidal anti-inflammatory drugs (NSAIDs) are added directly to phospholipid-containing oil such as lecithin oils or to a bio-compatible oil to which an phospholipid has been added to make a NSAID-containing formulation that possess low gastrointestinal (GI) toxicity and enhanced therapeutic activity to treat or prevent inflammation, pain, fever, platelet aggregation, tissue ulcerations and/or other tissue disorders. The composition of the invention are in the form of a non-aqueous solution, paste, suspension, dispersion, colloidal suspension or in the form of an aqueous emulsion or microemulsion for internal, oral, direct or topical administration.Type: ApplicationFiled: September 16, 2010Publication date: March 17, 2011Applicant: The Board of Regents of the University of Texas SystemInventor: Lenard M. Lichtenberger
-
Publication number: 20110065627Abstract: This invention describes a topical delivery mechanism that contains a mixture of cetylated fatty esters that act as transdermal carriers of desired therapeutic molecules. The proposed cetyl fatty ester penetrant-complex (Base CFEP-complex) contains specific cetyl fatty esters, polar solvents, a carrier base (gel, cream, lotion, patch or stick gel), antioxidants and the desired pharmaceutical, cosmetic or antigenic response eliciting molecules that are efficaciously delivered by selectively varying component ratios in the complex.Type: ApplicationFiled: October 29, 2009Publication date: March 17, 2011Applicant: CYMBIOTICS INC.Inventors: Raj R. Barathur, Jack Bain Bookout
-
Publication number: 20110052694Abstract: Described herein are microneedle drug delivery systems comprising a pharmaceutical compositions comprising pharmaceutically active agents (e.g., cannabidiol and prodrugs of cannabidiol) and microneedle arrays suitable for local and systemic delivery of the active agent to a mammal. Also described herein are methods of using a microneedle transdermal or topical drug delivery systems comprising pharmaceutical compositions, comprising cannabidiol and prodrugs of cannabidiol, and microneedle arrays in the treatment disease, including pancreatitis and pancreatic cancer.Type: ApplicationFiled: August 31, 2010Publication date: March 3, 2011Applicant: ALLTRANZ INC.Inventors: Audra Lynn Stinchcomb, Stan Lee Banks, Miroslaw Jerzy Golinski, Jeffery Lynn Howard, Dana Carmel Hammell
-
Publication number: 20110015134Abstract: This patent describes a method and materials to treat cancer diagnosed at an early stage, particularly breast cancer. It considers that metastatic breast cancer growth includes periods of dormancy, that surgery to remove a primary tumor can induce metastatic growth, and that women with Down Syndrome rarely get breast cancer. It elevates the level of an antiangiogenic drug produced by chromosome 21 preferably Endostatin in plasma preferably at least one day prior to surgery and kept at that high level preferably indefinitely. In one embodiment, the therapy specifically excludes drugs that significantly inhibit the VEGF pathway since that is important for wound healing. This method will prevent results of surgery from stimulating tumor growth and angiogenesis of micrometastatic disease that is much easier to prevent than control after the fact. This can be done indefinitely since there is no acquired resistance that develops, as happens in most cancer therapies.Type: ApplicationFiled: September 22, 2010Publication date: January 20, 2011Inventor: Michael W. Retsky
-
Publication number: 20100330174Abstract: The invention refers to the pharmaceutical combination including at least: a first compound selected among the group consisting of acetylsalicylic acid, salicylic acid, pharmaceutical derivatives thereof, and a second compound selected from the group consisting of lipidic betaines, betaines lipids, betaines of Formula (CH3)3N+(CH2)nCOO? with n an integer from 1 to 5, pharmaceutically acceptable salts thereof, esters thereof, precursors thereof, and mixtures thereof, with the proviso that the second compound is different from the first compound and in an amount by weight at least three times the amount of first compound.Type: ApplicationFiled: August 25, 2010Publication date: December 30, 2010Applicant: BIO ETHIC SPRL.Inventors: Jallal Messadek, Rachid Ennamany, Michel Thiry
-
Patent number: 7858569Abstract: Antibacterial solution useful as a cleaning agent suitable for cutaneous use by humans or otherwise which is aqueous based, free of alcohol and surfactants and having a quaternary ammonium compound as its principal antimicrobial agent, a number of moisturizing agents and DMDM Hydantoin serving at least as a preservative.Type: GrantFiled: March 30, 2005Date of Patent: December 28, 2010Assignee: Water Journey Ltd.Inventors: Francine Glick, Eugene Puchalski, Jr., Annette Joubert
-
Publication number: 20100323987Abstract: The invention relates to pharmaceutical combinations of retigabine and sodium channel inhibitors for treating, pains which are accompanied by an increase in muscle tone.Type: ApplicationFiled: August 30, 2010Publication date: December 23, 2010Applicant: Valeant Pharmaceuticals North AmericaInventors: Istvan SZELENYI, Kay BRUNE, Robert HERMANN, Mathias LOCHER
-
Publication number: 20100323995Abstract: The present invention provides compositions and methods for prevention and prophylaxis of neurological diseases accompanied by neuronal death. The invention includes synthesis of 5-benzylamino salicylic acid (BAS) and its derivatives. BAS and its derivatives protect cortical neurons from toxic insults by N-methyl-D-aspartate, Zn2+, and reactive oxygen species. Thus, the present invention provides compositions and methods for treating stroke, traumatic brain and spinal cord injury, epilepsy, and neurodegenerative diseases that are accompanied by severe neuronal loss via excitotoxicity, Zn2+ neurotoxicity, and free radical neurotoxicity.Type: ApplicationFiled: May 24, 2010Publication date: December 23, 2010Applicant: NEUROTECH PHARMACEUTICALS CO., LTD.Inventors: Byoung Joo GWAG, Young Ae LEE, Bo Rum RYU, Sung Hwa YOON, Ho Sang MOON
-
Publication number: 20100311700Abstract: A transdermal preparation for external use which contains a photosensitive NSAID and a UV blocker having a high ability to migrate into the skin. Thus, it becomes possible to ensure, in a transdermal preparation for external use containing a NSAID, the inhibition of the onset of light-induced non-immunological or immunological skin symptoms by the above-described component.Type: ApplicationFiled: April 29, 2010Publication date: December 9, 2010Applicant: Hisamitsu Pharmaceutical Co., Inc.Inventors: Kazuhisa Yoshitake, Kenji Atarashi, Tetsuji Kuwahara, Koichi Ikesue, Michinori Sakai, Yoshiaki Hashimoto, Kiyomi Tsuruda
-
Publication number: 20100286099Abstract: A water-soluble aspirin-theanine cocrystal composition which includes a quantity of acetylsalicylic acid and a quantity of a theanine enantiomer associated with the quantity of acetylsalicylic acid. The composition may be created by a method including the steps of: (i) providing a quantity of acetylsalicylic acid; (ii) adding a quantity of a theanine enantiomer to the quantity of acetylsalicylic acid to form a mixture comprising the quantity of acetylsalicylic acid and the enantiomer of theanine; (iii) wetting the mixture; and (iv) grinding the mixture for a length of time sufficient to produce a dried crystalline mass. The water-soluble cocrystal composition is suitable for intravenous administration, preferably to humans.Type: ApplicationFiled: May 8, 2009Publication date: November 11, 2010Inventors: Harry G. Brittain, Philip V. Felice
-
Publication number: 20100278917Abstract: Methods and formulations for treating inflammatory bowel disease are disclosed. The methods and formulations include, but are not limited to, methods and formulations for delivering effective concentrations of 4-aminosalicylic acid and/or 5-aminosalicylic acid to affected areas of the intestine. The methods and formulations comprise modified-release elements, providing for drug delivery to the affected or desired area. Diseases and conditions treatable with the present invention include Crohn's disease and ulcerative colitis.Type: ApplicationFiled: June 10, 2010Publication date: November 4, 2010Inventors: John Devane, Jackie Butler
-
Patent number: 7825106Abstract: Methods and formulations for treating inflammatory bowel disease are disclosed. The methods and formulations include, but are not limited to, methods and formulations for delivering effective concentrations of 4-aminosalicylic acid and/or 5-aminosalicylic acid, and pharmaceutically acceptable salts and pro-drugs thereof, to affected areas of the intestine, i.e., distal gut. The methods and formulations comprise modified-release elements, providing for drug delivery to the affected or desired area. Diseases and conditions treatable with the present invention include Crohn's disease and ulcerative colitis.Type: GrantFiled: March 10, 2006Date of Patent: November 2, 2010Assignee: AGI Therapeutics Ltd.Inventors: John Devane, Jackie Butler
-
Publication number: 20100267640Abstract: The present invention provides a method of attenuating the formation or reducing the severity of neurogenic swelling and/or neurogenic inflammation in the tissue of a patient via applying a composition comprising a hydrophilic foam substrate and a polymeric hydrophilic agent to a portion of the surface of the skin in an amount and at a location sufficient to attenuate formation of or reduce the severity of neurogenic swelling and/or neurogenic inflammation.Type: ApplicationFiled: April 26, 2010Publication date: October 21, 2010Applicant: Sessions Pharmaceuticals, Inc.Inventors: Robert W. Sessions, Alan R. Kahn
-
Publication number: 20100261686Abstract: The management of pain specially chronic pain often requires the use of opiate like medications which have a large number of undesirable effects, the most important one being habituation and addiction. The present invention consists of an integrated combination of medications acting through different mechanisms that are just as powerful as opiates in the management of pain without many of the undesirable side effects such as habituation and addiction.Type: ApplicationFiled: April 10, 2009Publication date: October 14, 2010Inventor: Jacques Benoit
-
Publication number: 20100261684Abstract: As many as 60% of patients who experience an acute coronary syndrome die before they even reach a hospital or other health care facilities, hence the importance of an effective treatment that the patient can self-administer at the first symptom or sign of an acute coronary syndrome. That treatment needs to act rapidly, to be easy to use, to be effective, to be safe, and readily available. The present invention describes a pharmaceutical combination containing a beta blocker agent, one or more anti-platelet agent(s) and a coronary vaso-dilator agent all included in a dose format to be taken orally or by sublingual spray to prevent myocardial infarction.Type: ApplicationFiled: April 13, 2009Publication date: October 14, 2010Inventor: Jacques Benoit
-
Publication number: 20100249080Abstract: A personal care composition comprising a eutectic mixture, the eutectic mixture comprising a CB receptor activating agent, in which the CB receptor is preferably palmitoylethanolamide. A method of mitigating scalp itch.Type: ApplicationFiled: November 11, 2008Publication date: September 30, 2010Inventors: Jason Shaun Burry, Richard Livesey Evans, Caroline Alexandra Hall, Ezat Khoshdel, Colina Mackay
-
Publication number: 20100239552Abstract: This invention is directed to pharmaceutical combinations comprising an antioxidant agent, an anti-inflammatory agent, and optionally at least one other anti-diabetic agent useful for treating metabolic disorders. This invention also encompasses pharmaceutically acceptable compositions comprising an antioxidant agent, an anti-inflammatory agent, optionally at least one other anti-diabetic agent, and at least one pharmaceutically acceptable carrier.Type: ApplicationFiled: March 16, 2010Publication date: September 23, 2010Applicant: GENMEDICA THERAPEUTICS SLInventors: Eric Mayoux, Luc Marti Clauzel, Silvia Garcia-Vicente, Marta Serrano Munoz, Antonio Zorzano Olarte, Alec Mian
-
Publication number: 20100221330Abstract: An oral control release formulation for releasing at least one betaine after oral administration to a human, said formulation comprising at least one pharmaceutically acceptable means ensuring an at least partial floating of the formulation releasing at least one betaine in the gastro-intestinal tractus.Type: ApplicationFiled: February 11, 2010Publication date: September 2, 2010Inventor: Jallal Messadek
-
Publication number: 20100189669Abstract: Personal care compositions containing an active selected from the group consisting of phlorogine, phlorgine BG, deoxyArbutin, sucrose dilaurate, bakuchiol, pyrenoine, millet, arlatone dioic acid, cinnamic acid, ferulic acid, achromaxyl, methyl nicotinamide, oil soluble licorice extract, folic acid, undecylenic acid, zinc undecylenate, L-tryptophan, thiamine HCl, hexylresorcinol, lipidami red vine, dragosine, methyl gentisate, inositol, symdiol 68, laminaine, their salts, their derivatives, their precursors, and/or combinations thereof. Methods for regulating the condition of mammalian keratinous tissue by topically applying the personal care compositions are also provided.Type: ApplicationFiled: January 25, 2010Publication date: July 29, 2010Inventor: Tomohiro Hakozaki